For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Privia Health Group Inc’s stock clocked out at $23.05, down -1.58% from its previous closing price of $23.42. In other words, the price has decreased by -$1.58 from its previous closing price. On the day, 0.58 million shares were traded. PRVA stock price reached its highest trading level at $24.005 during the session, while it also had its lowest trading level at $22.84.
Ratios:
To gain a deeper understanding of PRVA’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.42 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.89. For the most recent quarter (mrq), Quick Ratio is recorded 1.67 and its Current Ratio is at 1.67. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, RBC Capital Mkts on January 09, 2026, initiated with a Outperform rating and assigned the stock a target price of $31.
On November 13, 2025, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $30.
On January 10, 2025, Needham started tracking the stock assigning a Buy rating and target price of $25.Needham initiated its Buy rating on January 10, 2025, with a $25 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 12 ’25 when Morris Matthew Shawn sold 13,647 shares for $25.01 per share. The transaction valued at 341,311 led to the insider holds 68,188 shares of the business.
Mountcastle David sold 23,887 shares of PRVA for $597,892 on Dec 12 ’25. The EVP & Chief Financial Officer now owns 172,909 shares after completing the transaction at $25.03 per share. On Dec 12 ’25, another insider, Matthew Shawn Morris, who serves as the Director of the company, bought 833,340 shares for $24.91 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRVA now has a Market Capitalization of 2835185152 and an Enterprise Value of 2453705216. As of this moment, Privia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 162.32, and their Forward P/E ratio for the next fiscal year is 73.00. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.39 while its Price-to-Book (P/B) ratio in mrq is 3.99. Its current Enterprise Value per Revenue stands at 1.201 whereas that against EBITDA is 65.806.
Stock Price History:
The Beta on a monthly basis for PRVA is 0.83, which has changed by 0.08576727 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, PRVA has reached a high of $26.51, while it has fallen to a 52-week low of $18.77. The 50-Day Moving Average of the stock is -3.55%, while the 200-Day Moving Average is calculated to be 0.12%.
Shares Statistics:
It appears that PRVA traded 727.26K shares on average per day over the past three months and 602260 shares per day over the past ten days. A total of 122.87M shares are outstanding, with a floating share count of 114.72M. Insiders hold about 6.73% of the company’s shares, while institutions hold 93.82% stake in the company. Shares short for PRVA as of 1767139200 were 2568130 with a Short Ratio of 3.53, compared to 1764288000 on 3103782. Therefore, it implies a Short% of Shares Outstanding of 2568130 and a Short% of Float of 3.7600000000000002.
Earnings Estimates
. The current assessment of Privia Health Group Inc (PRVA) involves the perspectives of 11.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.22, with high estimates of $0.28 and low estimates of $0.15.
Analysts are recommending an EPS of between $0.97 and $0.88 for the fiscal current year, implying an average EPS of $0.94. EPS for the following year is $1.05, with 11.0 analysts recommending between $1.2 and $0.77.
Revenue Estimates
In. The current quarter, 15 analysts expect revenue to total $516.61M. It ranges from a high estimate of $552.1M to a low estimate of $493M. As of. The current estimate, Privia Health Group Inc’s year-ago sales were $460.9MFor the next quarter, 15 analysts are estimating revenue of $544.13M. There is a high estimate of $572.4M for the next quarter, whereas the lowest estimate is $516M.
A total of 15 analysts have provided revenue estimates for PRVA’s current fiscal year. The highest revenue estimate was $2.13B, while the lowest revenue estimate was $2.07B, resulting in an average revenue estimate of $2.1B. In the same quarter a year ago, actual revenue was $1.74BBased on 15 analysts’ estimates, the company’s revenue will be $2.31B in the next fiscal year. The high estimate is $2.39B and the low estimate is $2.22B.
